Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent-Reference-Cited by-同舟云学术

Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent

Published:2023-11 Issue:41 Volume:29 Page:3312-3323
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Rakhimov Radmir R.¹^ORCID,Sultanbaev Aleksandr V.¹^ORCID,Izmailov Adel A.¹^ORCID,Menshikov Konstantin V.¹^ORCID,Zabelin Vadim M.²^ORCID,Izmailov Albert A.³^ORCID,Gilyazova Gulshat R.⁴^ORCID,Izmailova Svetlana M.⁵^ORCID,Bakhtiyarova Ksenia S.⁶^ORCID,Izmailova Angelina A.⁷,Gilyazova Irina R.⁸^ORCID

Affiliation:

1. Department of Antitumor Drug Therapy, Republican Clinical Oncological Dispensary, Ufa, Republic of Bashkortostan, Russia

2. Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia

3. Department of Urology, P.A. Hertzen Moscow Oncology Research Institute, Moscow, Russia

4. Faculty of General Medicine, Bashkir State Medical University, Ufa, Russia

5. Department of Biology, Bashkir State Medical University, Ufa, Russia

6. Laboratory of Molecular Genetics, Institute of Urology and Clinical Oncology, Bashkir State Medical University, Ufa, Russia

7. Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia

8. Laboratory of Human Molecular Genetics, Institute of Biochemistry and Genetics, Ufa Federal Research Center of the Russian Academy of Sciences, Ufa, Russia

Abstract

Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms. Method: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by applying modern target drugs and immunotherapy. Result: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy. Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.

Funder

Russian Science Foundation

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference29 articles.

1. Kaprin AD.; Starinskiy VV.; Shakhzadova AO.; Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: Herzen Moscow Research Oncological Institute-branch of the National Medical Research Center of Radiology 2022,252

2. Motzer R.J.; Tannir N.M.; McDermott D.F.; Arén Frontera O.; Melichar B.; Choueiri T.K.; Plimack E.R.; Barthélémy P.; Porta C.; George S.; Powles T.; Donskov F.; Neiman V.; Kollmannsberger C.K.; Salman P.; Gurney H.; Hawkins R.; Ravaud A.; Grimm M.O.; Bracarda S.; Barrios C.H.; Tomita Y.; Castellano D.; Rini B.I.; Chen A.C.; Mekan S.; McHenry M.B.; Wind-Rotolo M.; Doan J.; Sharma P.; Hammers H.J.; Escudier B.; Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018,378(14),1277-1290

3. Albiges L.; Tannir N.M.; Burotto M.; McDermott D.; Plimack E.R.; Barthélémy P.; Porta C.; Powles T.; Donskov F.; George S.; Kollmannsberger C.K.; Gurney H.; Grimm M.O.; Tomita Y.; Castellano D.; Rini B.I.; Choueiri T.K.; Saggi S.S.; McHenry M.B.; Motzer R.J.; Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020,5(6),e001079

4. Motzer R.J.; Escudier B.; George S.; Hammers H.J.; Srinivas S.; Tykodi S.S.; Sosman J.A.; Plimack E.R.; Procopio G.; McDermott D.F.; Castellano D.; Choueiri T.K.; Donskov F.; Gurney H.; Oudard S.; Richardet M.; Peltola K.; Alva A.S.; Carducci M.; Wagstaff J.; Chevreau C.; Fukasawa S.; Tomita Y.; Gauler T.C.; Kollmannsberger C.K.; Schutz F.A.; Larkin J.; Cella D.; McHenry M.B.; Saggi S.S.; Tannir N.M.; Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 2020,126(18),4156-4167

5. McDermott D.F.; Drake C.G.; Sznol M.; Choueiri T.K.; Powderly J.D.; Smith D.C.; Brahmer J.R.; Carvajal R.D.; Hammers H.J.; Puzanov I.; Hodi F.S.; Kluger H.M.; Topalian S.L.; Pardoll D.M.; Wigginton J.M.; Kollia G.D.; Gupta A.; McDonald D.; Sankar V.; Sosman J.A.; Atkins M.B.; Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015,33(18),2013-2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ipilimumab/nivolumab;Reactions Weekly;2024-02-17